Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ELCC-2022-1000x250

The ESMO Colloquia are innovative sessions within the congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

View the complete ELCC 2022 Congress programme

One Tumour, Many Faces: Optimising Testing, Targeting and Monitoring Oncogene-Addicted NSCLC beyond EGFR

ELCC21-Colloquia-Thumb

Thursday, 31 March 2022, 11:45 - 13:15 CEST (Central European Summer Time)
Congress Hall
View the ESMO Colloquium details

This educational activity is provided by ESMO and co-supported by Eli Lilly 

Learning objectives
  • To provide an update on molecular epidemiology, testing technologies and the role of molecular tumour boards for patients with advanced non-small cell lung cancer harbouring non-EGFR, rare molecular aberrations.
  • To provide an overview of therapeutic pathways available in non-EGFR oncogene-driven advanced non-small cell lung cancer.
  • To highlight state of the art management strategies for patients with RET-driven NSCLC, including disease control in sanctuary sites

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.